Company record
Harbin Jixianglong Biotech Co., Ltd.
1 FDA warning letter since 2023 and 2 recalls in the last 12 months.
Get an email the day FDA posts anything new about Harbin Jixianglong Biotech Co., Ltd..
Warning letters
-
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Mar 11 | Class II | Harbin Jixianglong Biotech Co., Ltd. Drug |
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer… CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution |
| Mar 11 | Class II | Harbin Jixianglong Biotech Co., Ltd. Drug |
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotec… CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution |